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Abstract
Background—Chlamydia and gonorrhea infections can lead to serious and costly sequelae in 
women, but sequelae in men are rare. In accordance with the Centers for Disease Control and 
Prevention guidelines, female jail inmates in Maricopa County (Phoenix area), Arizona, are 
screened for these infections. Owing to lack of evidence of screening benefits in men, male 
inmates are tested and treated based on symptoms only.
Methods—We developed a probabilistic simulation model to simulate chlamydia and gonorrhea 
infections in Maricopa County jail male inmates and transmissions to female partners per year. We 
estimated the cost-effectiveness of screening as the cost per infection averted. Costs were 
estimated from the perspective of the Maricopa County Department of Public Health and the 
Correctional Health Services.
Results—Compared with symptom-based testing and treating strategy, screening male arrestees 
of all ages and only those 35 years or younger yielded the following results: averted approximately 
556 and 491 cases of infection in women at a cost of approximately US $1240 and $860 per case 
averted, respectively, if screened during physical examination (between days 8 and 14 from entry 
to jail), and averted approximately 1100 and 995 cases of infections averted at a cost of US $1030 
and $710 per infection averted, respectively, if screened early, within 2 to 3 days from entry to 
jail.
Correspondence: Chaitra Gopalappa, PhD, Futures Institute, 41-A New London Tpke, Glastonbury, CT 06033. chaitrag@gmail.com 
or cgopalappa@futuresinstitute.org. 
Disclosure: All authors were government employees at the time of the study and do not have any financial conflicts of interest to 
disclose. There were no additional sources of funding supporting this work.
Chaitra Gopalappa’s work was conducted during employment at the Centers for Disease Control and Prevention. Current affiliation: 
Futures Institute, Glastonbury, CT
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the 
Centers for Disease Control and Prevention or the Maricopa County Department of Public Health.
HHS Public Access
Author manuscript
Sex Transm Dis. Author manuscript; available in PMC 2015 October 01.
Published in final edited form as:
Sex Transm Dis. 2013 October ; 40(10): 776–783. doi:10.1097/OLQ.0000000000000023.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Conclusions—Screening of male inmates incurs a modest cost per infection averted in women 
compared with symptom-based testing. Screening in correctional settings can be used by public 
health programs to reduce disease burden, sequelae, and associated costs.
Correctional facility inmates are at higher risk for sexually transmitted infections with rates 
considerably higher than those of the general population.1 In women, chlamydia (CT) and 
gonorrhea (GC) can cause serious and costly sequelae, including pelvic inflammatory 
disease, which can lead to chronic pelvic pain, ectopic pregnancy, and infertility. Estimates 
in the literature have indicated that screening and treating women for these infections so as 
to avert sequelae are cost-effective compared with symptom-based testing.2 The Centers for 
Disease Control and Prevention (CDC) and US Preventive Services Task Force provide 
guidelines and recommendations for screening women for these infections.3 The CDC does 
not provide similar guidelines for screening of male adults because the sequelae of male 
infection (epididymitis) are not severe.4 The US Preventive Services Task Force gives male 
screening for CT an “I” (incomplete evidence) rating, and cost-effectiveness analyses of 
male screening have reached varying conclusions.5 However, studies have estimated 
probable benefits of screening men in high-prevalence settings such as in jails.6 Although 2 
studies associated jail-based male screening programs with a reduction in disease burden in 
the community7,8 another study of a Philadelphia program found no such evidence.9
A pilot screening study conducted by the Arizona Arrestee Reporting Information Network 
(AARIN) indicates high prevalence rates of CT and GC infections among men and women 
in Maricopa County (Phoenix area) jails.10 Among male arrestees, 7% and 4.6% were tested 
positive for CT and GC, respectively, and among female arrestees, 10% and 5% were tested 
positive for CT and GC, respectively (see Table 1 for age-based rates). The reported cases of 
CT and GC in the general population in year 2010 were approximately 0.41% and 0.06% of 
Maricopa residents, respectively.10,11
The Maricopa County Correctional system provides medical care to more than 130,000 
persons per year, with annual operating costs of approximately $50 million per year.12 The 
Maricopa County Correctional Health Services (CHS) currently screens women arrestees 35 
years and younger for CT and GC infections during the time of physical examination (PE). 
Male arrestees are not screened because of the unavailability of evidence of screening 
benefits and limited resources. However, the high prevalence of infections among male 
arrestees in Maricopa jails evidenced in the AARIN study indicates that a large population 
of women could be exposed to untreated male infections and thus be put at risk for serious 
sequelae. We used available data on the Maricopa jail population, including local prevalence 
data from the AARIN study and demographics data from the Maricopa county jails, to 
simulate infection in jail inmates and transmission to female partners upon their release 
during 1 calendar year. We estimated the number of infections averted in women by 
screening of male inmates in Maricopa County jails compared with the current strategy of 
symptom-based testing and treating. We also estimated the costs incurred for such a 
screening program and cost-effectiveness as the cost per infection averted in women.
Gopalappa et al. Page 2
Sex Transm Dis. Author manuscript; available in PMC 2015 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
METHODS
Model
We developed a stochastic individual simulation model (in NetLogo 4.1.3 software) by 
individually simulating each male arrestee from the time of entry into jail to either, release 
from jail if person is not infected at the time of release (both uninfected and infected but 
treated before release), or until recovery from infection if person is infected at the time of 
release. We simulated 100,000 male inmates, which was approximately the number of 
inmates entering jails in Maricopa County each year. The time-unit in the simulation is a 
calendar day. Age at entry into jail (Table 1) and length of stay in jail (distributed as 39%, 
50%, 52%, 62%, 74%, and 99% stay in jail <1, 2, 3, 8, 14, and 365 days, respectively) for 
each person in the simulation were assigned to match those of male inmates in the Maricopa 
County jails. At the time of entry, the proportion of arrestees infected with CT, GC, or both 
was simulated to match the age-based prevalence of these infections reported in the AARIN 
pilot study. We assumed that there were no new infections during the duration of stay in jail. 
For those who were released from jail with infection, we simulated possible transmissions to 
women as follows. Upon release from jail, assuming a heterosexual population, each person 
was assigned a female partner and variables that defined the sexual relationship, such as 
duration of partnership, number of sex acts, and condom use. When a relationship ended, a 
person could have a new partner, and the sexual behavioral variables were reassigned with 
different values to define the new partnership. During each time-unit after release from jail, 
the probability that the infected inmate could transmit the infection to his uninfected female 
partner was calculated using the Bernoulli equation.
where p is the probability of transmission per time-unit, α and β are the probabilities of 
transmission per unprotected and protected sex act, respectively, n the number of sex acts 
for that time-unit, and f the proportion of protected sex acts. Transmission beyond that of 
infected persons released from jail to uninfected female partners was not modeled. See 
Tables 1 and 2 for a list of data parameters and assumptions used in the model. To model 
stochasticity among individual persons, where applicable, parameter values were assigned 
by drawing random numbers from probability distributions. The number of sex acts per 
person per year was uniformly distributed. For each new sexual partnership of a person, 
duration of the partnership was exponentially distributed with mean estimated using number 
of partners per year. The number of sex acts per partnership was assigned proportional to the 
duration. Condom use was distributed by age. The probability of transmission per sex act 
was determined based on a uniform distribution. The duration of infection was also 
uniformly distributed.
Scenarios
We simulated a population of 100,000 male inmates each under 5 scenarios: (1) symptom-
based testing: this was the baseline and is equivalent to the current scenario where male 
inmates who seek medical help based on symptoms are tested for CT and GC; (2) screen all 
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during PE: this scenario proposes screening all male arrestees for CT and GC during the 
routine PE offered to all inmates, which usually occurs between days 8 to 14 from the time 
of entry to jail; (3) screen all inmates 35 years or younger during PE: given that the 
prevalence of the infections was lower in the older population of jail inmates (Table 1) and 
to reflect current CDC screening recommendations for women in correctional facilities, this 
scenario proposes screening only male arrestees who are 35 years or younger during the 
routine PE; (4) screen all on days 2 to 3: given that approximately 62% to 74% of inmates 
are released from jail by the time of PE, this scenario proposes screening all male arrestees 
for CT and GC on the second or third day from the time of entry into jail; and (5) screen all 
inmates 35 years or younger on days 2 to 3: this scenario proposes screening only male 
arrestees who are 35 years or younger on the second or third day from the time of entry to 
jail.
In all scenarios, we made the following assumptions. Testing would be done using a urine-
based combination assay for both CT and GC. We assumed that 73% of all inmates in jail at 
the time of screening would agree to test, which is the proportion in Maricopa County jails 
accepting a PE. It takes approximately 2 to 3 days to receive test results and approximately 5 
to 7 days from time of test before an inmate who is tested positive receives treatment. All 
inmates who are tested positive and are in jail were provided with and accepted the 
necessary treatment. Infected inmates who were released from jail before this time were 
followed up and, if found (with a probability of 80% [expert opinion]), were treated. 
Chlamydia would be treated with 1 dose of azithromycin and GC or co-infection with 1 dose 
of azithromycin plus 1 dose of ceftriax-one. We kept track of test and treatment costs 
incurred by each inmate, which are covered by the CHS or by the Maricopa County 
Department of Public Health (MCDPH) (Table 3). In each scenario, we also assumed that 
infected inmates who were not tested while in jail but developed symptoms after release 
from jail would seek medical help, that is, get tested and treated outside the jail. We 
assumed that those costs would be incurred by a different entity outside of MCDPH or CHS 
and hence were not included in our analyses. Testing costs, treatment costs, and personnel 
wages for follow-up were provided by Maricopa County Health Department in 2011 dollars, 
and a microcosting direct measurement technique was used to estimate cost inputs. To 
derive the labor costs for follow-up and treatment, we multiplied the staff time associated 
with each activity by the compensation, that is, wages plus benefits.
Sensitivity Analysis
We test for the sensitivity of results on age-based proportion accepting screening, age-based 
length of stay in jail, earlier availability of treatment for those infected, and additional cost 
of early screening, that is, on days 2 to 3 instead of with PE (Table 4).
Evaluation Measures
Under each scenario, using the simulation model, we estimated the number of infections in 
women, that is, transmissions from infected male inmates after release from jail, and the 
testing and treatment costs incurred by the CHS and MCDPH. For every scenario, we ran 
the simulation 30 times each with 100,000 inmates to obtain mean and confidence interval 
values of the results. All costs are in 2011 dollars. We estimated the average cost-
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effectiveness of scenarios 2 through 5 by dividing the net cost of a scenario by the net 
number of infections averted compared with scenario 1. By arranging scenarios in order of 
effectiveness, that is, decreasing order in number of new infections in women, we also 
estimated incremental cost-effectiveness ratios (ICERs) as incremental cost per infection 
averted in pairwise comparisons of a strategy with the next most effective strategy and 
eliminated weakly dominated scenarios. A scenario is weakly dominated if its ICER is 
greater than that of a more effective scenario, and hence, if all scenarios are feasible and 
acceptable, weakly dominated scenarios can be eliminated. We then reestimated ICERs 
among the remaining scenarios. In “Results,” we round estimated values to the nearest 10th 
unit.
RESULTS
In all scenarios, of the 100,000 inmates entering jail each year, approximately 10,330 were 
estimated to be infected with CT or GC at the time of entry (Table 5). Under the baseline 
scenario (scenario 1), where male inmates were tested and treated for CT and GC only if 
they sought medical help because of occurrence of symptoms, approximately 2150 infected 
inmates had received treatment by time of release from jail, whereas the rest of the 8160 
inmates were still infected and unaware of their infection at the time of release. Upon release 
from jail, these infected inmates transmitted the infection to approximately 6090 women. 
Scenario 1 cost approximately $114,960, of which, 50% was incurred by CHS and the 
remaining 50% by MCDPH.
Under the scenario where all male inmates were offered CT and GC screening along with 
their PE (scenario 2), which occurred anywhere between days 8 and 14 from the time of 
entry to jail, approximately 2600 infected inmates had received treatment by time of release 
from jail, whereas the rest of the 7740 remained infected and unaware of their infection at 
the time of release. The infected inmates comprised those who were released before testing 
day or did not accept the test (6930) and those who were tested but released from jail before 
the test results became available (810). These male inmates transmitted the infection to 
approximately 5530 women. When only inmates 35 years or younger were offered screening 
along with their PE (scenario 3), of the infected male inmates, approximately 2570 were 
tested and treated before release, approximately 7050 infected male inmates left jail before 
screening day or declined testing, and the remaining 740 infected male inmates were tested 
but had left the jail before receiving results. These infected men transmitted the infection to 
approximately 5600 women. Therefore, although a smaller population was screened in 
scenario 3 compared with scenario 2, given the lower prevalence of CT and GC and data 
indicating lower sexual risk behavior among older male population than younger men, there 
was not much difference in the number of transmissions. Scenarios 2 and 3 cost 
approximately $802,540 and $535,930, respectively. In scenario 2, testing and treatment 
incurred 92% and 8% of total cost, respectively. In scenario 3, testing and treatment incurred 
88% and 12% of total cost, respectively. In both scenarios, CHS and MCDPH incurred 59% 
and 41% of the total cost, respectively.
When all inmates were offered the test on days 2 to 3 from he time of entry to jail instead of 
delaying until PE day (scenario 4), there were approximately 7140 inmates with infection at 
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the time of their release from jail. The released infected inmates comprised approximately 
5730 inmates who had either left the jail before test day or refused to get tested and had 
1,410 inmates who were tested but released before their test results were available. When 
only inmates 35 years or younger were offered the test on days 2 to 3 from the time of entry 
to jail (scenario 5), there were approximately 7250 with infection at the time of release, 
including approximately 1280 who had been tested but had not yet received test results by 
the time of release. Infected male inmates in scenarios 4 and 5 transmitted the infection to 
approximately 5000 and 5090 women, respectively. Scenarios 4 and 5 cost approximately 
$1,249,460 and $819,740, respectively. In scenario 4, testing and treatment incurred 92% 
and 8% of total cost, respectively. In scenario 5, testing and treatment incurred 89% and 
11% of total cost, respectively. In both scenarios, CHS and MCDPH incurred 59% and 41% 
of the total cost, respectively.
Compared with baseline, scenarios 2 and 3 prevented approximately 560 and 490 cases of 
infection in women, respectively, whereas scenarios 4 and 5 prevented approximately 1100 
and 995 cases, respectively. Average cost-effectiveness, that is, the average cost per 
infection averted compared with the baseline (scenario 1), was approximately $1240, $860, 
$1030, and $710 in scenario 2, 3, 4, and 5, respectively (Table 5). Pairwise comparisons to 
estimate ICERs indicated that scenarios 2 and 3 were weakly dominated and, hence, were 
eliminated (Table 6). Pairwise comparisons among the remaining scenarios resulted in 
ICERs of approximately $710 and $4130 per infection averted in scenarios 5 and 4, 
respectively, compared with their next effective alternative (Table 6).
Sensitivity analyses indicate that scenario 5 has the least cost per infection averted compared 
with baseline in all cases, except for when the additional cost of screening early (on days 2–
3) is $7 per inmate, in which case scenario 3 has the least cost (Fig. 1). Infections averted in 
women were the highest when there was a faster turnaround of test results and treatment 
availability (Table 7).
DISCUSSION
Estimates indicate that offering CT and GC screening for male inmates in Maricopa jails 
followed with treatment for those infected could avert a large number of infections in 
women that could have been transmitted by infected male inmates released from jail. 
Although screening all male inmates averted the most cases of infections compared with 
screening only younger inmates, it was also relatively costly. Results suggest that screening 
only inmates 35 years or younger has the potential to avert a considerable number of 
infections in women. Only approximately 26% to 38% of inmates stay in jail longer than 8 
to 14 days (time of PE) and, as such, implementing the screening as soon as possible 
following arrest should be considered. Screening early, within 2 to 3 days when 48% to 50% 
are still in jail, averted twice the number of infections. Screening male inmates 35 years or 
younger on days 2 to 3 of entry to jail has the least cost per infection averted compared with 
symptom-based testing if early screening has no additional costs or is less than $7 per 
inmate screened. If early screening costs an additional $7 or more per inmate screened then 
screening inmates 35 years or younger on PE day had the least cost per infection averted 
compared with symptom-based testing.
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The model is subject to certain limitations. We estimated costs of testing and treatment of 
CT and GC only and did not include costs averted from sequelae in men or infection and 
sequelae in women. We estimated only first-level transmission and did not include any of 
the downstream transmissions from the infected women to others. We also did not include 
the potential impact of partner services. We assumed sexual behavior equivalent to the 
general population, but it is likely that some of the inmates are involved in higher-risk 
behavior. All of the above could have underestimated costs averted and infections averted. 
Also, individual programs may face different costs for specimen collection or testing and 
lead to results that differ from what we found.
Public health programs and correctional health systems are frequently faced with priority 
versus resource challenges. Our estimates indicate that screening male inmates for CT and 
GC could avert a considerable number of infections and hence possibly prevent cases of 
costly sequelae in women. These results are consistent with studies on screening at similar 
high-prevalence settings.13,14 Averting these infections could possibly translate to reducing 
disease burden in the community, as indicated in some studies.7,8 Another study that did not 
find any such evidence showed an unaccounted decrease in infections in the community in 
both control and case groups.9 The costs incurred per infection averted are within range of 
costs incurred in other screening programs that indicate that screening of men for CT and 
GC is cost-effective in high-prevalence settings.5,13 Our results indicate that, from the 
perspective of MCDPH and CHS, screening male inmates 35 years or younger has a lower 
incremental cost per infection averted compared with screening male inmates of all ages, 
which is consistent with CDC’s guidelines for screening women.4 Early screening and 
treatment availability could avert the most infections. In conclusion, in addition to screening 
women for early detection of CT and GC for prevention of severe sequelae, screening men 
in high-prevalence settings such as jails could prevent the occurrence of these infections in a 
large number of women.
Acknowledgments
The authors would like to acknowledge David Choate, Program Operations Manager, Center for Violence 
Prevention and Community Safety, Arizona State University, for help with data from the pilot screening study of 
jail inmates conducted by the Arizona Arrestee Reporting Information Network.
References
1. Hammett TM. Sexually transmitted diseases and incarceration. Curr Opin Infect Dis. 2009; 22:77–
81. [PubMed: 19532084] 
2. Roberts TE, Robinson S, Barton P, et al. Screening for Chlamydia trachomatis: A systematic review 
of the economic evaluations and modelling. Sex Transm Infect. 2006; 82:193–200. [PubMed: 
16731666] 
3. Screening for chlamydial infection: U S Preventive Services Task Force recommendation statement. 
Ann Intern Med. 2007; 147:128–134. [PubMed: 17576996] 
4. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR 
Recomm Rep. 2010; 59:1–110. [PubMed: 21160459] 
5. Gift TL, Blake DR, Gaydos CA, et al. The cost-effectiveness of screening men for Chlamydia 
trachomatis: A review of the literature. Sex Transm Dis. 2008; 35(suppl 11):S51–S60. [PubMed: 
18520977] 
Gopalappa et al. Page 7
Sex Transm Dis. Author manuscript; available in PMC 2015 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
6. Owusu-Edusei K Jr, Gift TL, Chesson HW, et al. Investigating the potential public health benefit of 
jail-based screening and treatment programs for chlamydia. Am J Epidemiol. 2013; 177:463–473. 
[PubMed: 23403986] 
7. Broad J, Cox T, Rodriguez S, et al. The impact of discontinuation of male STD screening services at 
a large urban county jail: Chicago, 2002–2004. Sex Transm Dis. 2009; 36(suppl 2):S49–S52. 
[PubMed: 19131909] 
8. Barry PM, Kent CK, Scott KC, et al. Is jail screening associated with a decrease in Chlamydia 
positivity among females seeking health services at community clinics? —San francisco, 1997–
2004. Sex Transm Dis. 2009; 36(suppl 2):S22–S28. [PubMed: 18418298] 
9. Peterman TA, Newman DR, Goldberg M, et al. Screening male prisoners for Chlamydia 
trachomatis: Impact on test positivity among women from their neighborhoods who were tested in 
family planning clinics. Sex Transm Dis. 2009; 36:425–429. [PubMed: 19525892] 
10. Choate, D. Alert on STDs. Arizona Arrestee Reporting Information Network; Arizona: Jun. 2011 
Available at: http://cvpcs.asu.edu/sites/default/files/content/products/AARIN_STD_brief.pdf [last 
accessed 7/29/2012]
11. Arizona Department of Health Services. [Accessed July 26, 2012] Arizona Health Status and Vital 
Statistics 2010 report. p. 5FAvailable at http://www.azdhs.gov/plan/report/ahs/index.htm
12. Correctional Health Services, Maricopa County, Arizona. [Accessed October 6, 2012] Available 
at: http://www.maricopa.gov/Corr_Health/About_Us.aspx
13. Kraut-Becher JR, Gift TL, Haddix AC, et al. Cost-effectiveness of universal screening for 
chlamydia and gonorrhea in US jails. J Urban Health. 2004; 81:453–471. [PubMed: 15273268] 
14. Gift TL, Lincoln T, Tuthill R, et al. A cost-effectiveness evaluation of a jail-based chlamydia 
screening program for men and its impact on their partners in the community. Sex Transm Dis. 
2006; 33(suppl 10):S103–S110. [PubMed: 17003677] 
15. Chandra A, Mosher WD, Copen C, et al. Sexual behavior, sexual attraction, and sexual identity in 
the United States: Data from the 2006–2008 National Survey of Family Growth. Natl Health Stat 
Report. 2011:1–36. [PubMed: 21560887] 
16. Herbenick D, Reece M, Schick V, et al. Sexual behaviors, relationships, and perceived health 
status among adult women in the United States: Results from a national probability sample. J Sex 
Med. 2010; 7(suppl 5):277–290. [PubMed: 21029385] 
17. Reece M, Herbenick D, Schick V, et al. Condom use rates in a national probability sample of 
males and females ages 14 to 94 in the United States. J Sex Med. 2010; 7:266–276. [PubMed: 
21029384] 
18. Stamm, WE. Chlamydia trachomatis infections in the adult. In: Holmes, KK.; Sparling, PF.; 
Stamm, WE., et al., editors. Sexually Transmitted Diseases. New York, NY: McGraw-Hill; 2008. 
p. 575-593.
19. Garnett GP, Mertz KJ, Finelli L, et al. The transmission dynamics of gonorrhoea: Modelling the 
reported behaviour of infected patients from Newark, New Jersey. Philos Trans R Soc Lond B 
Biol Sci. 1999; 354:787–797. [PubMed: 10365404] 
20. Kretzschmar M, van Duynhoven YT, Severijnen AJ. Modeling prevention strategies for gonorrhea 
and chlamydia using stochastic network simulations. Am J Epidemiol. 1996; 144:306–317. 
[PubMed: 8686700] 
21. Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted diseases: The case for 
screening. Prev Med. 2003; 36:502–509. [PubMed: 12649059] 
22. Quinn TC, Gaydos C, Shepherd M, et al. Epidemiologic and microbiologic correlates of 
Chlamydia trachomatis infection in sexual partnerships. JAMA. 1996; 276:1737–1742. [PubMed: 
8940322] 
23. Warner L, Newman DR, Austin HD, et al. Condom effectiveness for reducing transmission of 
gonorrhea and chlamydia: The importance of assessing partner infection status. Am J Epidemiol. 
2004; 159:242–251. [PubMed: 14742284] 
24. Handsfield HH, Lipman TO, Harnisch JP, et al. Asymptomatic gonorrhea in men. Diagnosis, 
natural course, prevalence and significance. N Engl J Med. 1974; 290:117–123. [PubMed: 
4202519] 
Gopalappa et al. Page 8
Sex Transm Dis. Author manuscript; available in PMC 2015 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
25. Hethcote, HW.; Yorke, JA. Gonorrhea Transmission Dynamics and Control: Lecture Notes in 
Biomathmatics. New York: Springer; 1984. 
26. Schachter J, Hook EW, Martin DH, et al. Confirming positive results of nucleic acid amplification 
tests (NAATs) for Chlamydia trachomatis: All NAATs are not created equal. J Clin Microbiol. 
2005; 43:1372–1373. [PubMed: 15750110] 
27. Dize L, Agreda P, Quinn N, et al. Comparison of self-obtained penile-meatal swabs to urine for the 
detection of C. trachomatis, N. gonorrhoeae and T. vaginalis. Sex Transm Infect. 2012; 89:305–
307. [PubMed: 23093735] 
28. Koumans EH, Black CM, Markowitz LE, et al. Comparison of methods for detection of Chlamydia 
trachomatis and Neisseria gonorrhoeae using commercially available nucleic acid amplification 
tests and a liquid pap smear medium. J Clin Microbiol. 2003; 41:1507–1511. [PubMed: 12682137] 
29. Geisler WM. Management of uncomplicated Chlamydia trachomatis infections in adolescents and 
adults: Evidence reviewed for the 2006 Centers for Disease Control and Prevention sexually 
transmitted diseases treatment guidelines. Clin Infect Dis. 2007; 44(suppl 3):S77–S83. [PubMed: 
17342671] 
30. Barbee LA, Kerani RP, Dombrowski JC, et al. A retrospective comparative study of 2-drug oral 
and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea. Clin Infect Dis. 
2013
Gopalappa et al. Page 9
Sex Transm Dis. Author manuscript; available in PMC 2015 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
Average cost-effectiveness measure (in dollars per infection averted compared with baseline 
symptom-based testing scenario) under sensitivity analyses.
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TABLE 2
Assumptions for Epidemiologic, Testing, and Treatment Parameters for CT and GC
Variable Value/Range Source
Epidemiologic variables For CT
 Incubation period, d* 7–21 18
 Duration of infection, d*
  Symptomatic, men 10–21 19,20
  Asymptomatic, men 120–365
 Proportion of CT infections that are symptomatic 0.5 18,21
 Transmission probability male to female per unprotected sex act 0.56–0.84 22
 Relative risk of transmission with condoms 0.42 23
Epidemiologic variables For GC
 Incubation period, d* 8 19
 Duration of infection, d* 19,20
  Symptomatic, men 12
  Asymptomatic, men 180
 Proportion of GC infections that are symptomatic, male 0.6 21,24
 Transmission probability male to female per unprotected sex act 0.5–0.7 25
 Relative risk of transmission with condoms 0.42 23
Test and treatment efficacy
 Test performance, %
  CT sensitivity (NAAT) 86.8 26,27
  GC sensitivity (NAAT) 88.9 26,27
  CT specificity (NAAT) 98.3 28
  GC specificity (NAAT) 99.5 28
 Treatment efficacy, %
  Azithromycin (1 g) against CT 96.5 29
  Azithromycin (1 g) and ceftriaxone against GC 89 30
*
For each inmate, duration of infection was a random number between the lower and upper bounds. For asymptomatic cases, the number of days 
into the infection at the time of entry to jail was a random number between 0 and the assigned length of infection plus incubation period. Assuming 
persons who show symptoms before entry to jail would have sought medical help, for symptomatic persons, the number of days into the infection 
at the time of entry to jail was a random number between 0 and length of incubation period; that is, symptoms occur only after entry to jail.
NAAT indicates nucleic acid amplification test.
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TABLE 3
Unit Costs (per Inmate) of Testing and Treatment
Variable Cost* Incurred by CHS Cost* Incurred by MCDPH
Test costs per inmate tested in jail 18.18† 11.30‡
Treatment costs if infected inmate is in jail at time of receiving treatment§
 CT infection 8.82
 GC infection or CT and GC coinfection 10.11
Cost to find inmate if released from jail before receiving treatment¶ 41.91
Treatment costs if inmate released from jail before receiving treatment||
 CT infection 22.74
 GC infection or CT and GC coinfection 25.24
Source: MCDPH and CHS; costs determined using microcosting direct measurement.
*All costs are in 2011 US dollars.
†Aptima CT/GC combo test kit.
‡Cost for NAAT for CT and GC test (including test reagents, collection, amplification reagent, tips, requisitions, and other disposable items) and 
processing of sample (including courier delivery of specimens to and from laboratory and labor costs for clinicians and technicians for processing 
specimen).
§
Treatment costs include costs for drugs and indirect costs in obtaining and delivering drugs.
¶
Labor costs to follow-up and perform disease investigation duties.
||
Includes cost for drugs and labor costs of clinicians in the MCDPH clinics.
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TABLE 4
Sensitivity Analyses Parameters
Parameter Base Value Sensitivity Analysis Value
Proportion accepting screening for CT and GC 73% for all ages a. 80% for age ≤35 y and 60% for age >35 y
b. 60% for age ≤35 y and 80% of >35 y
Proportion of inmates leaving jail by days 8 to 14 from time of entry to jail 74% for all ages a. 90% for age ≤35 y and 51% for age >35 y
b. 60% for age ≤35 y and 96% for age >35 y
Length of time from day of test for treatment availability for those infected 5–7 d 3–4 d
Additional cost of screening on days 2–3 (applicable for scenarios 4 and 5 
only), $ per inmate screened
$0 a. $5
b. $7
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